(glatiramer acetate) 20mg
Copaxone® 20mg is indicated for the treatment of relapsing forms of multiple sclerosis. It is not indicated for primary or secondary progressive forms of multiple sclerosis (see Section 5.1 of the Summary of Product Characteristics).1
The recommended dosage in adults is Copaxone® 20mg (one pre-filled syringe), administered as a subcutaneous injection once daily.1
Copaxone® 20mg safety profile in relapse remitting MS is confirmed by long-term studies up to 22 years.2-5
Of patients receiving continuous Copaxone® 20mg as sole immunomodulatory therapy for 15 years, 82% (n=100) remained ambulatory without mobile aids.6
Copaxone® comes in a prefilled syringe which is compatible with CSYNCTM.
The CSYNCTM has an ergonomic design and well positioned button for easy injection. Its audio and visual indicators also provide patients reassurance of dose delivery.
Patients should be instructed in self-injection techniques and should be supervised by a healthcare professional the first time they self-inject and for 30 minutes after.1
A different site should be chosen each day, so this will reduce the chances of any irritation or pain. Sites for self-injection include abdomen, arms, hips and thighs.1
Copaxone® (glatiramer acetate) is available in two dosage forms: 20mg/mL daily subcutaneous injection and 40mg/mL three times weekly subcutaneous injection.The average molecular weight of glatiramer acetate mixture is in the range of 5,000-9,000 Daltons. Due to its compositional complexity, no specified polypeptide can be fully characterized in terms of amino acid sequence, although the final glatiramer acetate composition is not entirely random.1
For a full list of excipients, See section 6.1. of the Summary of Product Characteristics.
Teva Pharmaceuticals Ltd
Marketing Authorisation Number(s)
1 Copaxone® (glatiramer acetate) 20mg Summary of Product Characteristics.
2 Johnson KP. Expert Rev Neurother 2012; 12(4): 371–384.
3 Boster A, Bartoszek MP, O’Connell C, et al. Ther Adv Neurol Disord 2011; 4(5): 319–332.
4 Miller A, Spada V, Beerkircher D, et al. Mult Scler 2008; 14(4): 494–499.
5 Hillert J. Mult Scler 2013; 19(1): 26–28.
6 Ford C, Goodman AD, Johnson K, et al. Mult Scler 2010; 16(3): 342–350.
To access this section of the Teva UK Limited website you need to be a member of the healthcare profession
because the materials included in this area of our website are specifically prepared for that audience
To understand why that is - please visit: Working in a regulated environment
Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.